In the world of clinical trials, it is not uncommon that in the middle of a study, there can be unexpected shifts in budget and unanticipated change orders, which have the potential to jeopardize an entire program if not handled correctly. To better prepare for these instances, the following clinical operations experts have come together to provide insight into the significance of meticulous contract examination when choosing an outsourcing partner:
- Raul P. Lima, Executive Vice President of Clinical Operations, inSeption Group
- Audrey Rossow, Director of Clinical Operations, Precirix
- Patricia Leuchten, Founder and CEO, Diligent Pharma
- Steven Zelenkofske, D.O. ,M.S., FACC, FCCP, FACOI, Principal Consultant/Board Director/CSO, SLZ Consulting LLC/Dinaqor AG and Cadrenal Therapeutics/Dinaqor AG
During the presentation, the speakers provide a comprehensive CRO Contract Checklist covering common warning signals to watch out for, essential inquiries, and optimal strategies to protect your trial's financial plan. By the end of this webinar, viewers will be better equipped to shoulder financial responsibilities, grasp essential needs for adaptability and innovation within a CRO contract, identify indications of a contract structured to prioritize the CRO's financial interests and understand the role of artificial intelligence in assessing and comparing bids.
Watch the video below and be empowered to assert control over clinical studies and communicate trial expectations.